You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion’s Mother and Child Health campaign for Asia and MEA announced

Details were unveiled during our first televised Regional Distributor Meeting on July 14th-15th

read more 

CORPORATE

COVID-19. Kedrion partners with Columbia University Irving MC

Kedrion and Columbia University release video statements

read more 

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

  1. CORPORATE - 04-10-2019

    Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY

    read more 

  2. EVENTS - 30-09-2019

    Kedrion reaffirms its commitment for the global eradication of Rh disease

    A worldwide initiative for maternal and fetal health launches in Florence, Italy

    read more 

  3. EVENTS - 17-07-2019

    Leading medical-scientific event on Hemophilia held in Trieste, Italy

    Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

    read more 

  4. EVENTS - 05-07-2019

    Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

    A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

    read more 

Pages

For more information please contact: pressoffice@kedrion.com